Abstract. Mucin1 (MUC1) is a transmembrane glycoprotein that plays a key role as an oncogene in the tumorigenesis of many human adenocarcinomas. However, the role of MUC1 in human hepatocellular carcinoma (HCC) progression remains unclear. In the present study, we silenced MUC1 to investigate its effect on the human HCC cell line SMMC-7721 and found that knockdown of MUC1 significantly inhibited cell proliferation, enhanced cell-cell aggregation and induced apoptosis. No significant differences were found in in vitro migration or invasion. We also observed that knockdown of MUC1 decreased the translocation of β-catenin to the nucleus, reduced the activity of T cell factor and blocked the expression of cyclin D1 and c-Myc. In addition, MUC1 knockdown enhanced the expression of E-cadherin, a molecular chaperone of β-catenin that plays an important role in cell-cell aggregation. In vivo assays demonstrated that there was no tumor growth in mice injected with MUC1-silenced cells. Global gene expression analysis showed that a series of genes encoding molecules in the Wnt/β-catenin, nuclear factor-κB (NF-κB), mitogen-activated protein kinase (MAPK), insulin, transforming growth factor β (TGF-β) and vascular endothelial growth factor (VEGF) signaling pathways were all influenced by the knockdown of MUC1, and these may contribute to the phenotypic alterations observed. Collectively, our results indicate that MUC1 plays a key role in HCC tumorigenesis.
Introduction
Mucin1 (MUC1), a transmembrane glycoprotein of the mucin family, is expressed on the apical surface of most glandular epithelia in normal tissue and is overexpressed in most adenocarcinomas with aberrant glycosylation and loss of apical expression (1) (2) (3) (4) (5) . MUC1 consists of a large extracellular N-terminal subunit containing a variable number of tandem repeats (VNTRs) region and a C-terminal subunit that resides on the cell surface as a heterodimeric complex via a strong noncovalent interaction. The C-terminal subunit is composed of a 58-amino acid extracellular domain, a 28-amino acid transmembrane domain (TM) and a 72-amino acid cytoplasmic tail (CT) (6) (7) (8) . MUC1-CT is highly conserved between different species and contains 7 tyrosine residues that can be phosphorylated by multiple kinases (9, 10) .
Previous studies have reported that aberrantly overexpressed MUC1 influences cell adhesion (11) , motility, migration, metastasis (12) (13) (14) and cell-cell aggregation (15) . Studies have shown that MUC1-CT is involved in many signaling pathways, including Wnt/β-catenin (16) , c-Src (17) , Grb2/Sos (18) , p53 (19, 20) , GSK3β (16) , EGFR (21, 22) and NF-κB (23, 24) , that regulate the processes of cell survival, proliferation and apoptosis. β-catenin is a major effector of the Wnt signaling pathway, and it interacts with MUC1-CT at an SXXXXXSSLS site. This interaction blocks the GSK3β-induced degradation of β-catenin and promotes the translocation of β-catenin to the nucleus. In the nucleus, β-catenin forms a complex with the transcription factors lymphoid enhancer factor/T cell factor (LEF/TCF) and activates the transcription of Wnt-responsive genes such as cyclin D1 and c-Myc to regulate cell proliferation (25, 26) . Further studies have demonstrated that MUC1 plays a key role as an oncogene in the formation and progression of lung (27) , breast (28) , ovarian (29) pancreatic and gastric carcinomas (30, 31) .
Several reports, including our studies, have shown that MUC1 is also expressed in hepatocellular carcinoma (HCC) cell lines, such as SNU-475, SNU-449, Mahlavu (32) and SMMC-7721, and in liver carcinoma, cirrhotic liver, and normal liver tissues (33) . However, the role of MUC1 in HCC progression remains unclear. In this study, we analyzed whether MUC1 plays a crucial role in HCC progression.
Materials and methods
Cell culture. The HCC cell line SMMC-7721 was purchased from the Cell Bank of the Shanghai Institute of Cell Biology, . Cells were screened with 1,200 µg/ml G418 for 3 weeks. Three independent MUC1-knockdown clones (MR1-C6, MR1-D4 and MR1-D9) and a negative control clone (NC) were isolated and identified by reverse transcription-polymerase chain reaction (RT-PCR) and western blotting.
RT-PCR and quantitative real-time PCR (qRT-PCR).
Cells were harvested, RNA was isolated using TRIzol (Invitrogen Life Technologies). Total RNA was converted to cDNA using M-MLV reverse transcriptase and oligo (dT) primers (Promega Corporation, Madison, WI, USA) according to the manufacturer's protocol. Reverse transcribed products were used to amplify MUC1 by RT-PCR using Ex Taq DNA polymerase (Takara Bio, Inc., Shiga, Japan). β-actin was used as an internal control gene. Primers sequences used for RT-PCR were: 5'-GGTCTTGCTGGTCTTAGGAGAGAC-3' (forward) and 5'-CTGAAGTCCAGCTGACCCTGTAGCTTCACG-3 (reverse) for MUC1, and 5'-GTTGCTATCCAGGCTGTGC-3' (forward) and 5'-AGCACTGTGTTGGCGTAAG-3' (reverse) for β-actin. The length of RT-PCR was 30 cycles. Amplification products were separated by 1.5% agarose gel, and DNA was visualized by a Gel Image System (Tanon). qRT-PCR was performed using a FastStart Universal SYBR-Green Master (Rox; Roche) on an ABI7300 instrument. The primer sequences used for qRT-PCR were: 5'-GCGTTTCCCAGAGTCATC-3' (forward) and 5'-CCTCCCTTCAACACTTCCT-3' (reverse) for cyclin D1, and 5'-TACATCCTGTCCGTCCAA-3' (forward) and 5'-TTTCCTTACGCACAAGAGTT-3' (reverse) for c-Myc, and 5'-AGTTGCGTTACACCCTTTC-3' (forward) and 5'-CCTTCACCGTTCCAGTTT-3' (reverse) for β-actin. The expression of each investigated gene was normalized to the housekeeping gene β-actin. Data were calculated using the 2 -∆∆CT method (34) and are presented as the fold change in gene expression relative to the negative control sample. For the negative control sample, 2 -∆∆CT
=1.
Cell viability assay. Cell viability was determined at different time points using a WST-1 cell viability assay according to the manufacturer's protocol (Roche Diagnostics, Mannheim, Germany). Triplicate wells containing 5x10 3 cells were evaluated for viability. The absorbance was measured using a microplate reader at a wavelength of 450 nm (BioTek Instruments, Inc., Winooski, VT, USA). The relative cell viability was calculated as the A450 nm (MUC1-silenced clones at Tn) / A450 nm (NC at Tn) x 100%.
Colony formation assay. Cells (2x10 3 ) were seeded into 6 well-plates for 3 weeks. Cell clones were stained with crystal violet staining solution (Sigma) and the colony size and number were observed. Colony numbers that contained >10 cells were counted and analyzed, the colony formation ratio was calculated as (colony number / seeded cell number) x 100%. Data are expressed as a ratio of the results obtained with each MUC1-knockdown clone and the negative control.
Cell cycle analysis. Cells (1x10 6 ) were harvested, washed with PBS, fixed with 70% ice-cold ethanol for 30 min and washed with PBS. Subsequently, cells were incubated in staining buffer with PI/RNase (BD Biosciences) for 30 min at 4˚C in the dark. The cell cycle was analyzed by flow cytometry (FACSCalibur; BD Biosciences).
Assays for cell migration and invasion. For migration assay, the scratch test was performed (35) . Matrigel invasion by cells was studied using transwell chambers with 8-µm pore size filters (Corning Incorporated, Corning, NY, USA) coated with Matrigel matrix (BD Biosciences) in a 24-well plate (36) .
Cell-cell aggregation assay. Constant stirring method was performed to evaluate the cell-cell aggregation (37) . Briefly, cells (2.5x10 5 ) were seeded into 24-well plates. Plates were incubated at 37˚C with constant stirring (150 rpm) for 2 h. Cells were then fixed with glutaraldehyde at time zero and at the end of the incubation. Aggregates were photographed under a microscope, and isolated cells were counted. The cell-cell aggregation index = 1 -(number of isolated cells at 2 h / number of isolated cells at 0 h) and was normalized to the data obtained with the negative control.
Annexin V-phycoerythrin staining analysis. Cells (1x10 5 ) were grown on slides in triplicate in 24-well plates and cultured for 48 h. Then, cells were washed with PBS and incubated in 500 µl binding buffer with 1 µl Annexin V-PE (BD Biosciences) for 15 min in the dark at room temperature. The slides were coverslipped with glycerol and then examined and imaged on an inverted fluorescence microscope (IX71; Olympus). Annexin V-positive cell rate was calculated as (Annexin V-positive cell number / total cell number) x 100%.
Western blot analysis. Western blotting was performed as previously described (36) . Briefly, cells were lysed with RIPA lysis buffer, and the protein concentrations in cell lysates were measured using a BCA protein assay Kit (Beyotime Biotechnology, Jiangsu, China). Nuclear and cytoplasmic protein extracts were isolated using a cytoplasmic and nuclear protein extraction kit (Thermo Scientific) according to the manufacturer's protocol. Equal amounts of cell lysate protein were separated by 10% SDS-PAGE and transferred to PVDF membranes (Millipore, Billerica, MA, USA). The primary antibodies used were antibodies against MUC1 (GP1.4) (1:2,000; NeoMarkers), c-Myc (1:1,000), cyclin D1 (1:1,000), β-actin (1:2,000), IκBα (1:2,000) and Lamin B1 (1:2,000; all from Epitomics, Burlingame, CA, USA), β-catenin (1:1,000; BD Biosciences), E-cadherin (Proteintech), caspase-3 (Santa Cruz Biotechnology).
Co-immunoprecipitation analysis. Cell lysates were first precleared with protein G agarose beads (Promega) for 3 h at 4˚C and, subsequently, equal amounts of sample lysate were incubated with either 1.0 µg of mouse IgG or anti-MUC1-CT antibody (Ab-5; Neomarker) for 16 h at 4˚C, followed by precipitation with protein G agarose beads. Immunoprecipitated proteins from cell lysates and total cell lysates were subjected to immunoblot analysis with anti-β-catenin.
Luciferase reporter assay. Cells were transfected using Lipofectamine 2000 (Invitrogen) according to the manufacturer's protocol with 1.0 µg/well of TOPflash and FOPflash plasmids (Upstate Biotechnology, Inc., Lake Placid, NY, USA) plus 0.05 µg/well of phRL-TK (Promega) to normalize transfection efficiency (36) .
In vivo tumor growth assays and immunohistochemical staining. BALB/c nude mice (4-6 weeks old) were purchased from Beijing HFK Bioscience Co., Ltd., China. Animals were maintained in specific pathogen-free conditions and environment under controlled conditions of light and humidity. Animal experiments were carried out in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Mice were randomly divided into 4 groups (5 animals/group), designated the SMMC-7721 group, the NC group, the MR1-C6 group and the MR1-D4 group. Cells (2x10 6 ) were subcutaneously injected into the right flank of each mouse. On day 35 post-injection, the tumors were dissected, fixed in 10% neutral-buffered formalin and embedded in paraffin for immunohistochemical staining using primary antibody mouse anti-MUC1 monoclonal antibody (GP1.4) and an UltraSensitiveTM SP (Mouse/Rabbit) IHC Kit (MaiXin.BIO., Fuzhou, China).
Global gene expression analysis by microarray. NC, MR1-C6 and MR1-D4 cells were harvested, and total RNA was isolated using TRIzol (Invitrogen Life Technologies) as described above. Global gene expression analysis was performed using Roche NimbleGen microarrays (Kang Chen Bio-tech, Shanghai, China).
Statistical analysis. All statistical analyses were performed using unpaired Student's t-tests, and P<0.05 was considered to indicate a statistically significant result.
Results

Establishment of stable MUC1 knockdown in SMMC-7721 cells.
To determine the effect of MUC1 expression in HCC, we silenced MUC1 in SMMC-7721 cells using RNAi. SMMC-7721 cells were transfected with MUC1-targeted or nonspecific siRNA in the expression vector pGCsilencer™U6.Neo. GFP. We identified three independent SMMC-7721-MUC1-knockdown stable cell clones (termed MR1-C6, MR1-D4 and MR1-D9) and a negative control clone termed NC by RT-PCR (Fig. 1A ) and western blotting (Fig. 1B) . These results showed that MUC1 expression in the MR1-C6, MR1-D4 and MR1-D9 cell clones was significantly decreased when compared to NC or SMMC-7721 cells (P<0.01). The silencing efficiency in clones MR1-C6 and MR1-D4 reached 82.34 and 74.53%, respectively. Therefore, we selected the MR1-C6 and MR1-D4 clones for subsequent studies.
Knockdown of MUC1 expression suppresses SMMC-7721 cell proliferation and arrests cells in S-phase.
To investigate the influence of MUC1 knockdown on SMMC-7721 cell proliferation, we performed WST-1 cell viability and colony formation assays. WST-1 assays showed that the viability of MR1-C6 and MR1-D4 clones was significantly reduced in a time-dependent manner when compared to NC or SMMC-7721 cells ( Fig. 2A ) (P<0.05). Colony numbers were decreased in MR1-C6 and MR1-D4 cells when compared to NC or SMMC-7721 cells (Fig. 2B) (P<0.05) . We also analyzed the cell cycle in MR1-C6, MR1-D4, SMMC-7721 and NC cells using flow cytometry. These results showed that MR1-C6 and MR1-D4 cells had a higher percentage of cells in the S-phase and fewer in the G0/G1 phase when compared to NC or SMMC-7721 cells (Fig. 2C) , demonstrating that knockdown of MUC1 in SMMC-7721 cells inhibits cell proliferation and induces cell cycle arrest in the S-phase.
Knockdown of MUC1 expression alters the β-catenin signaling pathway by blocking β-catenin translocation to the nucleus. Numerous reports have shown that MUC1 is involved in the β-catenin signaling pathway by binding to β-catenin. Therefore, we investigated the interaction between MUC1 and β-catenin in SMMC-7721 cells by co-immunoprecipitation. As shown in Fig. 3A , β-catenin was detected and was directly bound to MUC1-CT in SMMC-7721 cells. Furthermore, knockdown of MUC1 expression decreased the efficiency of the interaction between MUC1-CT and β-catenin. To evaluate the effect of MUC1 gene silencing on β-catenin subcellular localization, we used western blotting and showed that cytoplasmic β-catenin levels were significantly increased (Fig. 3B ) (P<0.05), while nuclear β-catenin levels were significantly decreased (Fig. 3C ) (P<0.05) in MR1-C6 and MR1-D4 cells when compared to NC or SMMC-7721 cells. These data indicate that knockdown of MUC1 blocks the translocation of β-catenin from the cytoplasm to the nucleus.
As the Wnt pathway is known to be involved in tumor cell proliferation, we performed a luciferase reporter assay to determine the effect of the MUC1-CT/β-catenin interaction on the activation of Wnt signaling in SMMC-7721 cells. The results showed that TOPflash/FOPflash reporter activity in MR1-C6 and MR1-D4 cells was significantly lower than the activity in NC cells (Fig. 3D) (P<0.05) . We used qRT-PCR and western blotting to evaluate the expression of cyclin D1 and c-Myc, which have been confirmed as target genes of the β-catenin signaling pathway that stimulate cell proliferation. As shown in Fig. 3E and F, knockdown of MUC1 significantly reduced both the mRNA and protein levels of cyclin D1 and c-Myc (P<0.05). The above data suggest that MUC1 gene silencing inhibits SMMC-7721 proliferation by ablating the β-catenin signaling.
Knockdown of MUC1 expression enhances cell-cell aggregation.
We examined the effect of MUC1 knockdown on the cell-cell aggregation, migration and invasion of SMMC-7721 cells. We developed a cell aggregation assay and examined the expression of E-cadherin, a molecular chaperone of β-catenin that plays an important role in cell aggregation. The results showed that the level of cell-cell aggregation and E-cadherin expression in the MR1-C6 and MR1-D4 cells were significantly enhanced when compared to NC or SMMC-7721 cells (Fig. 4A and B ) (P<0.05), indicating that knockdown of MUC1 may enhance cell-cell aggregation by promoting E-cadherin expression. In addition, we performed scratch test migration and Matrigel invasion assays and found no significant differences in migration or invasion between MR1-C6 or MR1-D4 cells and NC or SMMC-7721 cells (data not shown). Fig. 5A . Western blotting showed that caspase-3 cleavage was observed in MR1-C6 and MR1-D4 cells, while cleavage was not present in NC or SMMC-7721 cells (Fig. 5B) . Taken together, these results indicate that knockdown of MUC1 induces apoptosis in SMMC-7721 cells.
Knockdown of MUC1 expression induces apoptosis in
Knockdown of MUC1 expression suppresses tumor growth in vivo.
To evaluate the effects of MUC1 expression on tumorigenesis in vivo, SMMC-7721, NC, MR1-C6 and MR1-D4 cells were inoculated subcutaneously into BALB/c nude mice to establish a subcutaneous transplant tumor model. Thirty-five days after tumor implantation, mice were sacrificed, and the tumors were dissected. As shown in Fig. 6A , tumor growth was observed in both the NC and SMMC-7721 groups but not in the MR1-C6 and MR1-D4 groups. Immunohistochemical staining showed that MUC1 was significantly expressed by tumors from mice inoculated with SMMC-7721 and NC cells (Fig. 6B and C) . These results indicate that knockdown of MUC1 significantly suppresses SMMC-7721 tumor growth in vivo. Table I , some genes related to proliferation and aggregation were differentially expressed between clones MR1-C6 or MR1-D4 and NC. A series of genes encoding molecules that related to proliferation in the Wnt/β-catenin, NF-κB, MAPK, insulin, TGF-β and VEGF signaling pathways were expressed at significantly lower levels in the MUC1-knockdown clones MR1-C6 and MR1-D4. However, aggregation-related genes such as ICAM and FAT were expressed at significantly higher levels. These results indicate that knockdown of MUC1 influenced a number of signaling pathways related to cell proliferation and cell-cell aggregation in SMMC-7721 cells, affecting the occurrence and development of HCC.
Discussion
In the present study, we investigated the effects of MUC1 knockdown on the HCC cell line SMMC-7721. SMMC-7721-MUC1-knockdown stable clones were generated by RNA interference. We identified three independent MUC1-knockdown clones, MR1-C6, MR1-D4 and MR1-D9, and one negative control clone, NC, via immunofluorescence staining, PCR and western blotting. We selected the clones MR1-C6 and MR1-D4 due to their higher silencing efficiency and the NC clone to study in vitro cell proliferation, colony formation, cell cycle, migration, invasion, aggregation and cell apoptosis as well as to evaluate in vivo tumorigenesis.
We found that the MUC1-silenced clones MR1-C6 and MR1-D4 had significantly inhibited cell proliferation, similar to results described by Tsutsumida et al (38) , who showed that knockdown of MUC1 in pancreatic carcinoma cells (S2-013) significantly decreased cell proliferation. Raina et al (39) showed that 3Y1 cells overexpressing MUC1 could induce malignant transformation and enhance colony formation. Thus, we also utilized the colony formation assay to detect the effect of MUC1 gene silencing in MR1-C6 and MR1-D4 cells, showing a significant reduction in colony formation, further confirming that knockdown of MUC1 negatively regulated HCC cell proliferation. Subsequently, we performed cell cycle analysis and found that knockdown of MUC1 induced cell cycle arrest in the S-phase. In addition, we observed that knockdown of MUC1 induced apoptosis in SMMC-7721 cells, which is consistent with previous studies (40) (41) (42) . Moreover, tumor growth was not observed in mice injected with MR1-C6 and MR1-D4 cells. These results suggest that MUC1 plays an important role in HCC tumorigenesis. Several published studies (43) (44) (45) have shown that MUC1-CT interacts with β-catenin to form a complex and regulate the cellular localization of β-catenin. Nuclear translocation of β-catenin can activate cyclin D1 and c-Myc expression and stimulate cell proliferation, thus contributing to tumorigenesis and tumor progression. Our current study showed that MUC1-CT could interact with β-catenin and that knockdown of MUC1 in SMMC-7721 cells increased cytoplasmic levels of β-catenin but decreased the nuclear translocation of β-catenin, reduced the activity of TCF, downregulated expression of cyclin D1 and c-Myc, and arrested the cell cycle in S-phase. These results provide a potential mechanistic explanation of how MUC1 knockdown decreased the proliferation of SMMC-7721 cells in vitro.
To determine the effect of MUC1 on SMMC-7721 cell migration, invasion and aggregation, we conducted the scratch test, Matrigel invasion and aggregation assays, respectively. The results showed that knockdown of MUC1 promoted cell-cell aggregation when compared to controls. Cell-cell aggregation is mainly mediated by the cadherin complex, which can maintain epidermal morphogenesis of epidermal cells and is involved in cell-cell interactions. Yuan et al (46) showed that MUC1-silenced cells could increase the cell-cell aggregation of breast cancer cells and lead to higher expression of E-cadherin. Our result showed that E-cadherin expression was significantly increased in MR1-C6 and MR1-D4 cells, indicating that knockdown of MUC1 may enhance cell-cell aggregation by promoting E-cadherin expression. In addition, we found no significant differences in cell migration or invasion activity between MUC1-silenced clones and controls, which is consistent with Costa et al (37) . The reasons why MUC1 gene silencing did not affect HCC cell migration and invasion require further study.
To explore the mechanisms of MUC1 gene silencing that lead to inhibited cell proliferation and enhanced aggregation of SMMC-7721 cells, we further utilized microarrays to measure global gene expression and analyze differential gene expression between MUC1-silenced MR1-C6 or MR1-D4 cells and the NC cells. We showed that a series of genes encoding molecules in the Wnt/β-catenin, NF-κB, MAPK, insulin, VEGF and TGF-β signaling pathways were influenced by knockdown of MUC1, and these may contribute to the phenotypic alterations observed. However, the mechanisms underlying how MUC1 regulates TGF-β signaling pathway remain unclear and related experiments are being carried out.
In conclusion, our study shows for the first time that MUC1 expression influences the proliferation, apoptosis and cell-cell aggregation of HCC cell line SMMC-7721. These results indicate that MUC1 plays an important role in HCC tumorigenesis, and further suggest that MUC1 may be a potential target for HCC treatment.
